NanoLogix Inc. Appoints Two New Directors and Provides Operations Update

HUBBARD, Ohio, Jan. 12 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX) a
biotechnology company, announces director appointments and provides operations
update.

NanoLogix welcomes Daniel Barnhizer and Jeff Long to the Board of Directors.
Daniel Barnhizer is an associate professor of law at Michigan State University
College of Law, where he teaches and writes in the areas of business,
contract, securities, and commercial law. In addition to his academic work,
Professor Barnhizer also maintains an active consulting practice in corporate
and securities law. Prior to joining the MSU College of Law faculty in 2001,
Professor Barnhizer worked as a litigator in Washington, D.C. with the law
firms of Hogan & Hartson and Cadwalader, Wickersham & Taft, where his primary
practice areas focused on corporate governance, securities law, and white
collar criminal law. Professor Barnhizer graduated with honors from Harvard
Law School in 1995 where he was Managing Editor of the Harvard Environmental
Law Review.

Jeff Long is a novelist, historian, advertising writer, and human rights
advocate, He has authored eight novels, one of which was a New York Times
bestseller, and two non-fiction works. He has written and developed
advertising and catalogs for various companies including Overseas Adventure
Travel, Lowe Alpine Systems, Thompson Safaris, and others, and is the founder
of Witness Inc., a human rights and foreign aid group. Additional details
about Jeff are available on www.jefflongbooks.com

NanoLogix has secured additional square footage for the production of their
BNPTM Rapid Detection kits and is awaiting financing prior to the build-out of
the planned production clean-rooms and shipping/receiving area. The
additional area is adjacent to the existing NanoLogix headquarters and more
than doubles current company space in Hubbard, Ohio to approximately 4,000
square feet. The company also announces its intention to hold a 2009
shareholder meeting during the second quarter, with the date to be announced.

CEO Bret Barnhizer stated, "The addition of Daniel Barnhizer and Jeff Long to
our Board of Directors brings two very capable people to the Company ---
Daniel, for his expertise in multiple aspects of corporate and business law;
and Jeff Long, for both his advertising experience, business acumen, and an
outstanding ability to develop new paradigms. We look forward to their
contributions to the company." Director John Chatterton remarked: "I look
forward to working with our new Board Members and having Nanologix capitalize
on both their creativity and expertise."

Regarding the addition of space for production of BNPTM kits, Bret Barnhizer
said "All of us in NanoLogix are elated at the prospects for ramping up
production beyond the five-hundred per week capability of our Cincinnati
facility. The Hubbard expansion should provide the capability to produce
48,000 kits per week".

About NanoLogix, Inc.
NanoLogix is an industry innovator in the research, development, and
commercialization of biotechnologies, applications and processes. The Company
has multiple Patents and Patents Pending for rapid medical testing,
bioremediation, and Hydrogen Production utilizing bioreactor technology.
Information on NanoLogix is available at www.nanologixinc.com.

This press release contains statements, which may constitute "forward-looking
statements" within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix, Inc., and members of
its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by such
forward-looking statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions, the
occurrence of unanticipated events or changes to future operating results.

Contact:
Investor Relations
Carol Surrena
Telephone: 330-534-0800
E-mail: Carol@nanologixinc.com

SOURCE NanoLogix, Inc.

Investor Relations, Carol Surrena of NanoLogix, +1-330-534-0800,
Carol@nanologixinc.com